key: cord-0800660-rk0o0q3r authors: Albuquerque, J. O. M. d.; Kamioka, G. A.; Madalosso, G.; Costa, S. A.; Ferreira, P. B.; Pino, F. A.; Sato, A. P. S.; Carvalho, A. C. A. d.; Amorim, A. B. P.; Aires, C. C.; Kataoka, A. P. A. G.; Savani, E. S. M. M.; Bessa, T. A. F.; Aguiar, B. S. d.; Failla, M. A.; Santos, E. A. d.; Brito, E. M. T.; Santos, M. C. H. d.; Silva, S. M. S. e.; Caldeira, L. A. V.; Zamarco, L. C.; Fonseca, S. M. S.; Lima, M. M. d. C.; Marques, I. A.; Silva, F. E. V. d.; Glasser, P. R.; Burihan, P. C. P. R.; Cavazzana, C. L.; Lara, R. C.; Mello, D. S. d.; Pellini, A. C. G.; Nishio, F. Y.; Kian, F. M.; Braga, E. d. S. title: Prevalence evolution of SARS-CoV-2 infection in the Municipality of Sao Paulo, 2020 - 2021 date: 2021-06-20 journal: nan DOI: 10.1101/2021.06.16.21256530 sha: 4fe6ca66093a9f9e717132cbb68cc14acdce261c doc_id: 800660 cord_uid: rk0o0q3r Objectives: To estimate the evolution of the prevalence of SARS-CoV-2 virus infection among residents aged 18 years or over in the municipality of Sao Paulo. Methods: This is a population-based household survey conducted every 15 days, between June and September 2020 and January and February 2021. In total, 11 phases were performed. The presence of antibodies against SARS-CoV-2 was identified in venous blood using a lateral flow test, Wondfo Biotech. In the last phase, it was combined with an immunoenzymatic test, Euroimmun. Participants also answered a semi-structured questionnaire on sociodemographic and economic factors and social distancing measures. Prevalence estimates and 95% confidence intervals were estimated according to the region, Human Development Index, sex, age group, ethnicity, education, income and variables associated with risk or prevention of the infection. To compare the frequencies among the categories of each variable, the chi-square test with Rao Scott correction was used, considering a 5% significance level. Results: In total, 23,397 individuals were interviewed and had their samples collected. The estimated prevalence of antibodies against SARS-CoV-2 ranged from 9.7% (95%CI: 7.9-11.8%) to 25.0% (95%CI: 21.7-28.7). The prevalence of individuals with antibodies against SARS-CoV-2 was higher among black and pardo people, people with lower schooling, people with lower income and among residents of regions with lower Human Development Index. The lowest prevalences were associated with recommended measures of disease protection. The proportion of asymptomatic infection was 45.1%. Conclusion: The estimated prevalence of SARS-CoV-2 infection was lower than the cumulative incidence variation, except for the last phase of the study. The differences in prevalence estimates observed among subpopulations showed the social inequality as a risk of infection. The lower prevalence observed among those who could follow prevention measures reinforce the need to maintain the social distancing measures as ways to prevent SARS-CoV-2 infection. From the date of the first case until March 28, 2021, the disease was detected in 12,490,362 people and caused 310,550 deaths, the incidence rate was 5,943.6 per 100,000 inhabitants and the mortality rate was 147.8 per 100,000 inhabitants 4 . This serial serological survey was designed to represent people with 18 years or older in the MSP. Population-based data was needed to direct strategies to combat the pandemic and evaluate the effects of COVID-19 actions to prevent and control the disease. In this sense, our study aimed to estimate the prevalence of SARS-CoV-2 virus infection in adults with 18 years or older, living in the MSP; estimate the proportion of asymptomatic individuals with positive tests and describe the evolution of the prevalence of SARS-CoV-2 virus infection over time. This is a serial serological survey to estimate the prevalence of SARS-CoV-2 infection in the MSP. The MSP, the capital of the state of São Paulo, has a Human Development Index In 2020, a pilot study was performed in June and seven cross-sectional studies were repeated periodically in different samples, every 15 days, from June to September. In 2021, four other studies were repeated in January and February. In each phase, a stratified probabilistic sample with a simple casual sampling was used within each stratum 8 . For a prevalence ranging from 5% to 20%, the sample size was determined so that, the estimates were produced with coefficients of variation lower than 15% for the MSP and lower than 30% for the regions, with the exception of the Central . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2021. ; https://doi.org/10.1101/2021.06. 16.21256530 doi: medRxiv preprint and West regions, which have a smaller number of PHU. This process results in eight dwellings per stratum. The sample size was increased to 12 dwellings to maintain the accuracy of the estimates affected by the non-response (closed households or refusals to participate in the study). In the Central and West regions, the sample size per CA-PHU was also increased to 15 to also compensate the smaller number of PHU in the region (Table S1, supplementary material) . Statistically, this is a single stage sampling (the dwelling is the sample unit), however, operationally, the selection was made in two stages; in the second stage, the resident was selected in the household using the last birthday method. The selected person collected material for laboratory analyses and was interviewed. If the selected property was closed or the selected resident was not at home at the time of the visit, the PHU's team should return up to twice. The addresses of dwellings were accessed from a database composed by three different types of records updated between the study phases: a) residential Testing was performed using the SARS-CoV-2 Antibody test® (Wondfo Biotech, Guangzhou, China) that detects IgM/IgG antibodies against SARS-CoV-2, without discriminating the type of immunoglobulin. In Brazil, the test is distributed by MoH under the name One Step COVID-2019 Test® and the legal manufacturer is Celer Biotecnologia S/A 9 . The test is based on the principle of lateral flow immunochromatographic for the detection of IgG/IgM antibodies against SARS-CoV-2 in human blood, serum or plasma 10 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 20, 2021. ; https://doi.org/10.1101/2021.06. 16.21256530 doi: medRxiv preprint In this survey, venous blood samples were used to obtain the serum, since the validation study of the OneStep Wondfo Test indicated an increase of sensitivity with serum sample in comparison with capillary blood obtained by digital puncture. Pellanda et al 11 estimated a sensitivity of 84.8% and a specificity of 99.0% by assessing the results of four validated studies. In the last phase, to increase the sensitivity and the specificity of virus detection, the samples were also processed using an immunoenzymatic test (anti-SARS-CoV-2 ELISA) from EUROIMMUN, which uses the S1 spike protein as an antigen for the detection of IgG antibodies against SARS-CoV-2 in serum 12,13 . The official laboratory results were reported to the study participants. Participants were interviewed with a semi-structured questionnaire. The information collected were: sex, age, schooling, ethnicity (self-reported), family income, household size, symptoms potentially related to COVID-19, healthcare service use, previous SARS-CoV-2 test, contact history with suspected or confirmed cases of COVID-19. Also, the interviewees were questioned about their work regime, the social distancing adopted, facemask use, visit to nonessential places and public transportation use. Data were included in a standardized electronic form in FormSUS/DATASUS platform, version 3.0 14 . Data processing and analysis were performed using the statistical packages R and STATA version 13. Indeterminate results were classified in the analyses as negative. Data were analyzed considering five regions in the MSP: Central-West, East, North, Southeast and South. Prevalence estimates were weighted according to the sampling design. Prevalence with 95% confidence intervals (CI) were estimated according to the region and HDI of the MSP, sex, age, ethnicity, education, income and presence of symptoms of the individual, risk factors, recommended measures for prevention and control of the disease and social distancing. Also, the proportion of asymptomatic infections were calculated. For statistical data analyses, four phases were randomly chosen from the 11 phases performed in this study. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2021. ; https://doi.org/10.1101/2021.06.16.21256530 doi: medRxiv preprint Rao Scott chi-square test was used to compare the frequencies between the categories of each variable, considering a 5% significance level. The study was approved by the Brazilian's National Ethics Committee (CAAE 32947920.3.0000.0008). Blood sample were collected and the individual were interviewed only after written informed consent from all participants. Out of 63,372 selected individuals with 18 years or over, residing in the five regions of the municipality of São Paulo (MSP), 23,397 (36.9% participation rate) were interviewed and collected samples. Table 1 shows the prevalence estimates of antibodies against SARS-CoV-2 in the MSP and their respective 95% CI for each phase of the study. All values found were within the range of CI variation of the previous phases, except in the last phase, when two laboratory tests were used to increase the sensitivity and the specificity of virus detection. Table 2 shows the prevalence estimates of SARS-CoV-2 infection in phases 1, 4, 7 and 11. The results of phase 11 with only the rapid test (11a) and with the addition of the ELISA test (11b) are presented separately. The prevalence estimates of this study did not follow the evolution of the accumulated cases of SARS-CoV-2 infection in the MSP, except for the last phase as shown in Figure 2A . The design effect (deff) varied between the study phases, from 1.93 in phase 7 to 3.09 in the last phase; in phase 1, the deff was 2.71 and in phase 4; 2.95. The coefficients of variation of prevalence estimates for the municipality were below 15% in all phases and below 30% in all regions, except for the Central-West region. There was a significant difference between the regions of the municipality of São Paulo in phases 4 and 7 of the study. The Central-West region presented the lowest estimates, whereas the Southern region presented the highest. Table 2 also presents the prevalence estimates of SARS-CoV-2 infection, according to demographic and clinical characteristics. Regarding age, the estimated prevalences varied between the phases of the study, in phase 1, the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2021. ; https://doi.org/10.1101/2021.06.16.21256530 doi: medRxiv preprint highest prevalence was found in the age group from 50 to 64 years; in phase 4, from 18 to 34 years; in phase 7, from 35 to 49 years and in phase 11, from 18 to 34 years. Only in phase 7, the difference among age groups was significant. In all phases, women presented the highest prevalence, especially in phase 11, when the difference was statistically significant. The estimated prevalence of black and pardo people was the highest in all phases. There was a significant difference in ethnicity in all phases. The highest prevalence estimates were found in the groups with the lowest education levels. Table 2 Table 2 , the prevalence of cases without symptoms increased throughout the study phases. Table 3 shows the prevalence estimates of SARS-CoV-2 infection, according to socioeconomic factors and recommended measures adopted, for phases 1, 4, 7 and 11. Prevalence estimates were inverse to the categories of family income that were distributed in A/B (≥ R$ 8,641.00), C (R$ 2,005.00 to R$ 8,640.00) and D/E (≤ R$ 2,004.00). Moreover, HDI ranges were used to estimate the regional differences of the city, range A (0.84 to 0.95) had the lowest prevalence estimates whereas range C (0.62 to 0.73) presented the highest estimates. The difference among HDI ranges and family income categories were significantly different, except in phase 11 (Table 3) . Regarding the work situation of the interviewees, the study showed that those in telework had lower prevalence when compared to the other categories, especially in phases 1 and 4 (3.9% and 4.4%, respectively). Likewise, those who did not use public transportation and practiced social distancing presented the lowest prevalence estimates. The difference was significantly in phases 1 and 11. The difference between the categories for mask use, "always", "most of the time" and "sometimes" was significant in phase 11 (24.4%). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2021. to conduct the interview and sample collection. The non-response rate presented an increase trend throughout the study. The results showed that most people in MSP are still susceptible to the SARS- In 2020, several studies in Brazil and around the world aimed to estimate the prevalence of SARS-CoV-2 infection in their populations [15] [16] [17] [18] [19] [20] [21] . The results of different prevalence studies should be carefully compared, since they depend on the moment of the pandemic evolution and the laboratory test used 22 . In our study, the estimated prevalence of antibodies against SARS-CoV-2 in the MSP ranged from 9.7% (95%CI: 7.9-11.8) in phase 1 to 16% (95%CI: 13.1-19.3) in phase 10; in phase 11, when two laboratory tests were used, the estimate was 25% (95%CI: 21.7-28.7). In Brazil, Hallal et al. 20 conducted a large study involving two serological surveys in 133 sentinel cities in all Brazilian states, they used the same laboratory test of our study with finger prick blood samples and estimated prevalences between 0% and 25%. In the state of Espírito Santo, Gomes et al. 22 conducted a population-based serial cross-sectional study in 11 municipalities, they found a prevalence of 2.1% using the Celer Technologies Inc test in a finger prick blood sample. In the municipality of São Paulo, a study conducted in six administrative districts found a low prevalence (4.7%) using the MAGLUMI 2019-nCoV chemiluminescence immunoassay test 21 . In the present study, the highest prevalence estimates were initially found in the age group from 50 to 64 years, which is a vulnerable population most affected at the beginning of the pandemic. In the following phases, the younger age groups were the most prevalent, which is the economically active population that most circulates in the city. This fact may be associated with the economic recover of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Similar to other studies, there was no difference between the prevalence of men and women 16, 17, 20 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 20, 2021. ; https://doi.org/10.1101/2021.06.16.21256530 doi: medRxiv preprint World Health Organization. WHO Coronavirus disease (COVID-19) Pandemic. Geneva; 2020 Portaria nº 188 de 3 de fevereiro de 2020. Declara Emergência em Saúde Pública de importância Nacional (ESPIN) em decorrência Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York Pérez-Olmeda M et al on behalf of the ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based sero epidemiological study Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. medRxiv Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China A population-based study of the prevalence of COVID-19 infection in Brazil: methodology and results of the first stage Spatiotemporal ecological study of COVID-19 mortality in the city of São Paulo, Brazil: Shifting of the high mortality risk from areas with the best to those with the worst socio-economic conditions High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato